Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.75 |
| ▸ | CA12 | O43570 | 2/20 | 0.75 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.75 |
| ▸ | CA1 | P00915 | 2/20 | 0.75 |
| ▸ | CA2 | P00918 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | MAOA | P21397 | 2/20 | 0.75 |
| ▸ | CA4 | P22748 | 2/20 | 0.75 |
| ▸ | CA6 | P23280 | 2/20 | 0.75 |
| ▸ | CA5A | P35218 | 2/20 | 0.75 |
| ▸ | CA7 | P43166 | 2/20 | 0.75 |
| ▸ | BLM | P54132 | 2/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.75 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.75 |
| ▸ | CA9 | Q16790 | 2/20 | 0.75 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.75 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.75 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL9465678 | 0.98 | HRH2 (0.75) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL39237 | 0.87 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL973 | 0.87 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL458654 | 0.87 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL29384901 | 0.87 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28032679 | 0.86 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863201 | 0.86 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL22127098 | 0.86 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863206 | 0.85 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28528271 | 0.85 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| CN-1460477-A | Prpearation method of H2 receptor antagonist composite salt and its application | QI YOUMAO (CN) | 2003-12-10 | — | — | CN | disclosed |
| EP-0367484-B1 | Carboxylic acid derivates | GLAXO GROUP LTD (GB) | 1994-02-16 | — | — | EP | disclosed |
| US-5273984-A | Bismuth complex having a carboxylic acid to form a salt of the basic antagonist excluding ranitidine | GLAXO GROUP LIMITED (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0367484-A1 | Carboxylic acid derivates | GLAXO GROUP LIMITED (GB) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | HRH2 1743/4885SLC22A2 3444/4885CA12 2730/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | HRH2 1743/4885SLC22A2 3444/4885CA12 2730/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | HRH2 2157/4885SLC22A2 799/4885CA12 2235/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | HRH2 2498/4885SLC22A2 3264/4885CA12 1641/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | HRH2 1743/4885SLC22A2 3444/4885CA12 2730/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | HRH2 2157/4885SLC22A2 799/4885CA12 2235/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | HRH2 2428/4885SLC22A2 2912/4885CA12 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.